Lung mast cells and hypoxic pulmonary hypertension

Physiological Research

Volumn 61, Issue 1, 2012, Pages 1-11

  Maxova H ^a,b   Herget, J ^a,b   Vizek M ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Cardiovascular Research Center   (Czech Republic)

Author keywords

Hypoxia; Mast cells; Pulmonary hypertension; Tissue remodeling

Indexed keywords

ANIMAL; CELL HYPOXIA; HUMAN; MAST CELL; METABOLISM; PATHOLOGY; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; CELL HYPOXIA; HUMANS; HYPERTENSION, PULMONARY; MAST CELLS;

EID: 84861535749     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. AVIADO DM, SAMANEK M, FOLLE LE: Cardiopulmonary effects of tobacco and related substances. I. The release of histamine during inhalation of cigarette smoke and anoxemia in the heart-lung and intact dog preparation. Arch Environ Health 12: 705-711, 1966.
2. BANASOVA A, MAXOVA H, HAMPL V, VIZEK M, POVYSILOVA V, NOVOTNA J, VAJNEROVA O, HNILICKOVA O, HERGET J: Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 76: 102-107, 2008.
3. BARER GR: Reactivity of the vessels of collapsed and ventilated lungs to drugs and hypoxia. Circ Res 18: 366-378, 1966.
4. BARER GR, MCCURRIE JR: Pulmonary vasomotor responses in the cat; the effects and interrelationships of drugs, hypoxia and hypercapnia. Q J Exp Physiol Cogn Med Sci 54: 156-172, 1969.
5. BEAVEN MA: Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol 39: 11-25, 2009.
6. BERNSTEIN IL: Cromolyn sodium. Chest 87: 68S-73S, 1985.
7. BOERMA M, WANG J, KULKARNI A, ROBERTO KA, QIU X, KENNEDY RH, HAUER-JENSEN M: Influence of endothelin 1 receptor inhibition on functional, structural and molecular changes in the rat heart after irradiation. Radiat Res 170: 275-283, 2008.
8. CHAPMAN RE, SCOTT AA, DESCHAMPS AM, LOWRY AS, STROUD RE, IKONOMIDIS JS, SPINALE FG: Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol 35: 539-548, 2003.
9. COWAN KN, HEILBUT A, HUMPL T, LAM C, ITO S, RABINOVITCH M: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6: 698-702, 2000.
10. DAHAL BK, KOSANOVIC D, KAULEN C, CORNITESCU T, SAVAI R, HOFFMANN J, REISS I, GHOFRANI HA, WEISSMANN N, KUEBLER WM, SEEGER W, GRIMMINGER F, SCHERMULY RT: Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 12: 60, 2011.
11. DAWSON CA, DELANO FA, HAMILTON LH, STEKIEL WJ: Histamine releasers and hypoxic vasoconstriction in isolated cat lungs. J Appl Physiol 37: 670-674, 1974.
12. DUMAS DE LA ROQUE E, SAVINEAU JP, BONNET S: Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 126: 186-199, 2010.
13. EHRLICH P: Beiträge zur Theorie und Praxis der histologischen Färbung. Thesis, Liepzig University, 1878.
14. ESPOSITO I, FRIESS H, KAPPELER A, SHRIKHANDE S, KLEEFF J, RAMESH H, ZIMMERMANN A, BUCHLER MW: Mast cell distribution and activation in chronic pancreatitis. Hum Pathol 32: 1174-1183, 2001.
15. FAJARDO I, PEJLER G: Human mast cell beta-tryptase is a gelatinase. J Immunol 171: 1493-1499, 2003.
16. FRANCESCHINI B, CEVA-GRIMALDI G, RUSSO C, DIOGUARDI N, GRIZZI F: The complex functions of mast cells in chronic human liver diseases. Dig Dis Sci 51: 2248-2256, 2006.
17. FRANTZ EG, SCHREIBER MD, SOIFER SJ: Cromolyn sodium does not prevent hypoxia-induced pulmonary hypertension in newborn and young lambs. J Dev Physiol 10: 555-565, 1988.
18. FROSSI B, RIVERA J, HIRSCH E, PUCILLO C: Selective activation of Fyn/PI3K and p38 MAPK regulates IL-4 production in BMMC under nontoxic stress condition. J Immunol 178: 2549-2555, 2007.
19. GALLI SJ, TSAI M: Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 49: 7-19, 2008.
20. GARCIA-ROMAN J, IBARRA-SANCHEZ A, LAMAS M, GONZALEZ ESPINOSA C: VEGF secretion during hypoxia depends on free radicals-induced Fyn kinase activity in mast cells. Biochem Biophys Res Commun 401: 262-267, 2010.
21. GILFILLAN AM, RIVERA J: The tyrosine kinase network regulating mast cell activation. Immunol Rev 228: 149-169, 2009.
22. GORDON JR, GALLI SJ: Release of both preformed and newly synthesized tumor necrosis factor α (TNF-α)/cachectin by mouse mast cells stimulated via the FcεRI. A mechanism for the sustained action of mast cellderived TNF-α during IgE-dependent biological responses. J Exp Med 174: 103-107, 1991.
23. GREENLEE KJ, WERB Z, KHERADMAND F: Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 87: 69-98, 2007.
24. GROTE K, FLACH I, LUCHTEFELD M, AKIN E, HOLLAND SM, DREXLER H, SCHIEFFER B: Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 92: e80-e86, 2003.
25. GULLIKSSON M, CARVALHO RF, ULLERAS E, NILSSON G: Mast cell survival and mediator secretion in response to hypoxia. PLoS One 5: e12360, 2010.
26. HAAS F, BERGOFSKY EH: Role of the mast cell in the pulmonary pressor response to hypoxia. J Clin Invest 51: 3154-3162, 1972.
27. HAMPL V, HERGET J: Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 80: 1337-1372, 2000.
28. HAUGE A: Role of histamine in hypoxic pulmonary hypertension in the rat. I. Blockade or potentiation of endogenous amines, kinins, and ATP. Circ Res 22: 371-383, 1968.
29. HAUGE A, MELMON KL: Role of histamine in hypoxic pulmonary hypertension in the rat. II. Depletion of histamine, serotonin, and catecholamines. Circ Res 22: 385-392, 1968.
30. HEATH D, YACOUB M: Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 44: 1003-1006, 1991.
31. HELGESEN KG, BJERTNAES L: The effect of ketanserin on hypoxia-induced vasoconstriction in isolated lungs. Int J Microcirc Clin Exp 5: 65-72, 1986.
32. HERGET J, JEŽEK V: Pulmonary hypertension in chronic lung disease. In: Pulmonary Hypertension Problems and Controversies. DENOLIN H, WAGENVOORT CA (eds), Elsevier Publ. Co., Amsterdam, 1989, pp 142-162.
33. HERGET J, NOVOTNA J, BIBOVA J, POVYSILOVA V, VANKOVA M, HAMPL V: Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 285: L199-L208, 2003.
34. HERGET J, SUGGETT AJ, LEACH E, BARER GR: Resolution of pulmonary hypertension and other features induced by chronic hypoxia in rats during complete and intermittent normoxia. Thorax 33: 468-473, 1978..
35. HOFFMANN J, YIN J, KUKUCKA M, YIN N, SAARIKKO I, STERNER-KOCK A, FUJII H, LEONG-POI H, KUPPE H, SCHERMULY RT, KUEBLER WM: Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 37: 1400-1410, 2011.
36. HOWARD P, BARER GR, THOMPSON B, WARREN PM, ABBOTT CJ, MUNGALL IP: Factors causing and reversing vasoconstriction in unventilated lung. Respir Physiol 24: 325-345, 1975.
37. JACOB MP, BADIER-COMMANDER C, FONTAINE V, BENAZZOUG Y, FELDMAN L, MICHEL JB: Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 49: 326-332, 2001.
38. KARAKIULAKIS G, PAPAKONSTANTINOU E, ALETRAS AJ, TAMM M, ROTH M: Cell type-specific effect of hypoxia and platelet-derived growth factor-BB on extracellular matrix turnover and its consequences for lung remodeling. J Biol Chem 282: 908-915, 2007.
39. KAY JM, GROVER RF: Lung Mast Cells and Hypoxic Pulmonary Hypertension. Karger, Basel, 1975.
40. KAY JM, SUYAMA KL, KEANE PM: Mast cell stabilizing compound FPL 55618 reduces right ventricular hypertrophy and lung mast cell hyperplasia in chronically hypoxic rats. Experientia 37: 75-76, 1981.
41. KAY JM, WAYMIRE JC, GROVER RF: Lung mast cell hyperplasia and pulmonary histamine-forming capacity in hypoxic rats. Am J Physiol 226: 178-184, 1974.
42. KENNEDY RH, HAUER-JENSEN M, JOSEPH J: Cardiac function in hearts isolated from a rat model deficient in mast cells. Am J Physiol Heart Circ Physiol 288: H632-H637, 2005.
43. KITAMURA Y, GO S, HATANAKA K: Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52: 447-452, 1978.
44. KNAUPER V, LOPEZ-OTIN C, SMITH B, KNIGHT G, MURPHY G: Biochemical characterization of human collagenase-3. J Biol Chem 271: 1544-1550, 1996.
45. LACHMANOVA V, HNILICKOVA O, POVYSILOVA V, HAMPL V, HERGET J: N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci 77: 175-182, 2005.
46. LEVICK SP, GARDNER JD, HOLLAND M, HAUER-JENSEN M, JANICKI JS, BROWER GL: Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol 45: 56-61, 2008.
47. LEVICK SP, MELENDEZ GC, PLANTE E, MCLARTY JL, BROWER GL, JANICKI JS: Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89: 12-19, 2011.
48. MALTBY S, KHAZAIE K, MCNAGNY KM: Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796: 19-26, 2009.
49. MARGULIS A, NOCKA KH, WOOD NL, WOLF SF, GOLDMAN SJ, KASAIAN MT: MMP dependence of fibroblast contraction and collagen production induced by human mast cell activation in a three-dimensional collagen lattice. Am J Physiol Lung Cell Mol Physiol 296: L236-L247, 2009.
50. MASKOS K: Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 87: 249-263, 2005.
51. MAXOVÁ H, NOVOTNÁ J, VAJNER L, VÍZEK M, VYTÁŠEK R, HERGET J: Effect of N-acetylcysteine on tissue metalloproteinases activity in RBL-2H3 mast cells exposed to 24 hours of "in vitro" hypoxia. Physiol Res 53: 24P, 2004.
52. MAXOVA H, NOVOTNA J, VAJNER L, TOMASOVA H, VYTASEK R, VIZEK M, BACAKOVA L, VALOUSKOVA V, ELIASOVA T, HERGET J: In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells. Physiol Res 57: 903-910, 2008.
53. MAXOVA H, BACAKOVA L, ECKHARDT A, MIKSIK I, LISA V, NOVOTNA J, HERGET J: Growth of vascular smooth muscle cells on collagen I exposed to RBL-2H3 mastocytoma cells. Cell Physiol Biochem 25: 615-622, 2010a.
54. MAXOVA H, BACAKOVA L, LISA V, NOVOTNA J, TOMASOVA H, VIZEK M, HERGET J: Production of proteolytic enzymes in mast cells, fibroblasts, vascular smooth muscle and endothelial cells cultivated under normoxic or hypoxic conditions. Physiol Res 59: 711-719, 2010b.
55. MAXOVA H, VASILKOVA M, NOVOTNA J, VAJNEROVA O, BANASOVA A, VIZEK M, HERGET J: Prevention of mast cell degranulation by disodium cromoglycate delayed the regression of hypoxic pulmonary hypertension in rats. Respiration 80: 335-339, 2010c.
56. MCMURTRY IF, ABE K, OTA H, FAGAN KA, OKA M: Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 661: 299-308, 2010.
57. METCALFE DD, BARAM D, MEKORI YA: Mast cells. Physiol Rev 77: 1033-1079, 1997.
58. MIGALLY NB, TUCKER A, GREENLEES K, WRIGHT M, ZAMBERNARD J: Density and ultrastructure of mast cells in lung vessels of aging rats exposed to and recovering from chronic hypoxia. Cell Tissue Res 232: 601-608, 1983.
59. MONTANI D, PERROS F, GAMBARYAN N, GIRERD B, DORFMULLER P, PRICE LC, HUERTAS A, HAMMAD H, LAMBRECHT B, SIMONNEAU G, LAUNAY JM, COHEN-KAMINSKY S, HUMBERT M: C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 116-123, 2011.
60. MUHS BE, PATEL S, YEE H, MARCUS S, SHAMAMIAN P: Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res 109: 110-117, 2003.
61. MUNGALL IP: Hypoxia and lung mast cells: influence of disodium cromoglycate. Thorax 31: 94-100, 1976.
62. NADZIEJKO CE, LOUD AV, KIKKAWA Y: Effect of alveolar hypoxia on pulmonary mast cells in vivo. Am Rev Respir Dis 140: 743-748, 1989.
63. NAKANISHI I, TAJIMA F, NAKAMURA A, YAGURA SY, OOKAWARA T, YAMASHITA H, SUZUKI K, TANIGUCHI N, OHNO H: Effects of hypobaric hypoxia on antioxidant enzymes in rats. J Physiol 489: 869-876, 1995.
64. NORRBY K: Mast cells and angiogenesis. Apmis 110: 355-371, 2002.
65. NOVOTNA J, HERGET J: Exposure to chronic hypoxia induces qualitative changes of collagen in the walls of peripheral pulmonary arteries. Life Sci 62: 1-12, 1998.
66. NOVOTNA J, HERGET J: Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 51: 323-334, 2002.
67. OKADA K, TANAKA Y, BERNSTEIN M, ZHANG W, PATTERSON GA, BOTNEY MD: Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151: 1019-1025, 1997.
68. PEJLER G, RONNBERG E, WAERN I, WERNERSSON S: Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115: 4981-4990, 2010.
69. RABINOVITCH M, GAMBLE WJ, MIETTINEN OS, REID L: Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 240: H62-H72, 1981.
70. REID LM: Structure and function in pulmonary hypertension. New perceptions. Chest 89: 279-288, 1986.
71. RIBATTI D, CRIVELLATO E, MOLICA S: Mast cells and angiogenesis in haematological malignancies. Leuk Res 33: 876-879, 2009.
72. RILEY DJ, THAKKER-VARIA S, WILSON FJ, POIANI GJ, TOZZI CA: Role of proteolysis and apoptosis in regression of pulmonary vascular remodeling. Physiol Res 49: 577-585, 2000.
73. RILEY JF, WEST GB: Histamine in tissue mast cells. J Physiol 117: 72P-73P, 1952.
74. ROBIN ED, CROSS CE, MILLEN JE, MURDAUGH HV Jr: Humoral agent from calf lung producing pulmonary arterial vasoconstriction. Science 156: 827-830, 1967.
75. SHI K, QIAO LN, LIU B, ZHAO SS, ZHOU TF, WANG XM, WEI L, LIU HM, HUA YM: Effect of doxycycline on the development of pulmonary hypertension induced by four methods in rats. (In Chinese) Zhonghua Er Ke Za Zhi 47: 260-264, 2009.
76. SINGH M, SAINI HK: Resident cardiac mast cells and ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 8: 135-148, 2003.
77. STEINER DR, GONZALEZ NC, WOOD JG: Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 94: 325-334, 2003.
78. SWINDLE EJ, METCALFE DD: The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 217: 186-205, 2007.
79. TCHOUGOUNOVA E, LUNDEQUIST A, FAJARDO I, WINBERG JO, ABRINK M, PEJLER G: A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280: 9291-9296, 2005.
80. THAKKER-VARIA S, TOZZI CA, POIANI GJ, BABIARZ JP, TATEM L, WILSON FJ, RILEY DJ: Expression of matrix-degrading enzymes in pulmonary vascular remodeling in the rat. Am J Physiol 275: L398-L406, 1998.
81. TODOROVICH-HUNTER L, DODO H, YE C, MCCREADY L, KEELEY FW, RABINOVITCH M: Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis 146: 213-223, 1992.
82. TOZZI CA, THAKKER-VARIA S, YU SY, BANNETT RF, PENG BW, POIANI GJ, WILSON FJ, RILEY DJ: Mast cell collagenase correlates with regression of pulmonary vascular remodeling in the rat. Am J Respir Cell Mol Biol 18: 497-510, 1998.
83. TSUJIMURA T, HIROTA S, NOMURA S, NIWA Y, YAMAZAKI M, TONO T, MORII E, KIM HM, KONDO K, NISHIMUNE Y, ET AL.: Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood 78: 1942-1946, 1991.
84. TUCKER A, MCMURTRY I, ALEXANDER AF, REEVES JT, GROVER RF: Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 42: 174-178, 1977.
85. TUCKER A, WEIR EK, REEVES JT, GROVER RF: Failure of histamine antagonists to prevent hypoxic pulmonary vasoconstriction in dogs. J Appl Physiol 40: 496-500, 1976.
86. VAJNER L, VYTASEK R, LACHMANOVA V, UHLIK J, KONRADOVA V, NOVOTNA J, HAMPL V, HERGET J: Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 87: 383-391, 2006.
87. VAN ALBADA ME, BARTELDS B, WIJNBERG H, MOHAUPT S, DICKINSON MG, SCHOEMAKER RG, KOOI K, GERBENS F, BERGER RM: Gene expression profile in flow-associated pulmonary arterial hypertension with neointimal lesions. Am J Physiol Lung Cell Mol Physiol 298: L483-L491, 2010.
88. VIEILLARD-BARON A, FRISDAL E, EDDAHIBI S, DEPREZ I, BAKER AH, NEWBY AC, BERGER P, LEVAME M, RAFFESTIN B, ADNOT S, D'ORTHO MP: Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 87: 418-425, 2000.
89. VIEILLARD-BARON A, FRISDAL E, RAFFESTIN B, BAKER AH, EDDAHIBI S, ADNOT S, D'ORTHO MP: Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther 14: 861-869, 2003.
90. VYAS H, KRISHNASWAMY G: Paul Ehrlich's "Mastzellen" - from aniline dyes to DNA chip arrays. In: Mast Cells Methods and Protocols. KRISHNASWAMY G, CHI DS (eds), Humana Press Inc., Totowa, NJ, 2005, pp 3-11.
91. WARD JP, MCMURTRY IF: Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 9: 287-296, 2009.
92. YE CL, RABINOVITCH M: Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol 261: H1255-H1267, 1991.
93. ZAIDI SH, YOU XM, CIURA S, HUSAIN M, RABINOVITCH M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516-521, 2002.
94. ZEMPO N, KOYAMA N, KENAGY RD, LEA HJ, CLOWES AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 16: 28-33, 1996.
95. ZHU YJ, KRADIN R, BRANDSTETTER RD, STATON G, MOSS J, HALES CA: Hypoxic pulmonary hypertension in the mast cell-deficient mouse. J Appl Physiol 54: 680-686, 1983.